Buchumschlag

Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: a case report

Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TK...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Longuespée, Rémi (VerfasserIn) , Kunz, Julia (VerfasserIn) , Fresnais, Margaux (VerfasserIn) , Foerster, Kathrin (VerfasserIn) , Burhenne, Jürgen (VerfasserIn) , Thomas, Michael (VerfasserIn) , Kazdal, Daniel (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Christopoulos, Petros (VerfasserIn) , Haefeli, Walter E. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 2024
In: British journal of clinical pharmacology
Year: 2024, Jahrgang: 90, Heft: 1, Pages: 344-349
ISSN:1365-2125
DOI:10.1111/bcp.15924
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/bcp.15924
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15924
Volltext
Verfasserangaben:Rémi Longuespée, Julia Kunz, Margaux Fresnais, Kathrin I. Foerster, Jürgen Burhenne, Michael Thomas, Daniel Kazdal, Albrecht Stenzinger, Petros Christopoulos, Walter E. Haefeli
Beschreibung
Zusammenfassung:Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control.
Beschreibung:Erstveröffentlichung: 10. Oktober 2023
Gesehen am 06.02.2024
Beschreibung:Online Resource
ISSN:1365-2125
DOI:10.1111/bcp.15924

Ähnliche Einträge